Zealand Pharma initiated with a Hold at Deutsche Bank

Deutsche Bank initiated coverage of Zealand Pharma with a Hold rating and DKK 815 price target The firm says the stock’s valuation already reflects much of optimism for the opportunity around the company’s amylin asset petrelintide.